All the news Showing 4 of 24 articles from: AASLD 2015Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Ns5A inhibitors Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3 Liz Highleyman / 16 November 2015 An 8-week triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 showed a high sustained response rate in a phase 2 study of people with difficult-to-treat hepatitis C virus (HCV), including treatment-experienced people ... Hepatocellular carcinoma (HCC) Liver cancer risk will remain elevated for people with cirrhosis cured of hepatitis C Keith Alcorn / 16 November 2015 The burden of liver cancer and cirrhosis caused by hepatitis C is likely to continue to grow in the United States despite curative treatment for hepatitis C, and people who have cirrhosis ... New and experimental treatments for hepatitis B REP 2139 shows promise for people with hepatitis B and hepatitis delta co-infection Liz Highleyman / 16 November 2015 The nucleic acid-based polymer REP 2139, used first as monotherapy then combined with pegylated interferon, reduced hepatitis B surface antigen (HBsAg) levels, lowered hepatitis delta viral load and increased anti-HBs antibody titres, according ... Treatment for people who use drugs Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs Liz Highleyman / 16 November 2015 Merck's grazoprevir/elbasvir coformulation cured hepatitis C infection in 92% of injecting drug users receiving opioid substitution therapy in the C-EDGE CO-STAR study, according to a presentation on Sunday at the 2015 AASLD ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive